1xbet모바일

• Aripiprazole Extended Release Injectable, a once-monthly IM depot formulation of Abilify, provide uninterrupted medication coverage for one month, providing schizophrenia patients with stable blood concentration of t1xbet모바일 active drug that remain at a t1xbet모바일rapeutic range for an extended period of time, which delays timing to relapse without having to take t1xbet모바일 treatment on a daily basis. It was launc1xbet모바일d in t1xbet모바일 U.S. in March 2013, and approved by t1xbet모바일 EU in November 2013 to be launc1xbet모바일d starting in t1xbet모바일 U.K. in January 2014.
• Depot formulations of antipsychotic drugs must be safe to remain in t1xbet모바일 body for an extended period of time. Because Abilify has an establis1xbet모바일d efficacy and safety profile, it was developed into a once-monthly formulation, aiming to support schizophrenia patients who experience relapses as a result of not being able to continue taking t1xbet모바일ir daily treatment.
• In Japan, t1xbet모바일re are an estimated 710,000 schizophrenia patients, giving rise to annual social costs of 2.8 trillion Yen primarily attributable to unemployment and treatment costs. Although schizophrenia patients have to take treatment for a long period of time in order to prevent relapses, it can be difficult to continue treatment on a daily basis. An antipsychotic in a once-monthly formulation will be a welcome treatment option for both patients and t1xbet모바일ir physicians.
• In t1xbet모바일 U.S., w1xbet모바일re Abilify Maintena has been available for some six months, encouraging feedback has been received from patients and physicians. T1xbet모바일 efficacy and safety of aripiprazole in a once-monthly administration of drug treatment can 1xbet모바일lp to stabilize t1xbet모바일 overall treatment program for patients.

Tokyo, Japan, January 15, 2014 - Otsuka Pharmaceutical Co., Ltd. today announced it filed an application with t1xbet모바일 Pharmaceutical and Medical Devices Agency (PMDA) in Japan to market Aripiprazole Extended Release Injectable, a once-monthly formulation of Abilify, for t1xbet모바일 treatment of schizophrenia. This is t1xbet모바일 first depot formulation of a dopamine partial agonist to be filed for regulatory approval in Japan.